Metropolis Healthcare Limited (METROPOLIS) Earnings Call Transcript
November 4, 2026
Earnings Call Speaker Segments
Good day, everyone, and welcome to the Metropolis Healthcare Limited Q2 and H1 FY '27 Earnings Conference Call, hosted by BNP Paribas. This call may include forward-looking statements regarding the company, and those are based on the beliefs, opinions, and expectations of the company as of the date of this call. Such statements do not guarantee future performance and carry risks and uncertainties that are hard to predict. <<operator_script>> Kindly note that this conference is being recorded. I'll now turn the conference over to Mr. Tausif Shaikh. Thank you, and over to you, Mr. Shaikh.
Good morning, everyone. I'd like to welcome all of you to the Metropolis Healthcare 2Q FY '27 First Half Earnings Con Call. This is Tausif Shaikh, India analyst at BNP Paribas covering Pharma and Healthcare. We're grateful to the management for the chance to host this call. Representing the Metropolis team, we have the senior management led by Ameera Shah, Chairperson, Whole Time Director; Surendran Chemmenkotil, Managing Director; Sameer Patel, Chief Financial Officer; and Mohan Menon, Chief Marketing Officer. I'll now turn the call over to Ameera for her opening remarks. Over to you, ma'am.
Good morning, everyone, and thanks for being with us today on Metropolis Healthcare's Q2 FY '27 Earnings Conference Call. With me are Suren, our Managing Director; Sameer Patel, our CFO; Mohan Menon, our CMO; and the remainder of our leadership team, together with SGA, our Investor Relations partner. Our investor presentation has been uploaded on the exchanges and on the website, and I hope each of you has had an opportunity to review it. Let me begin with the highlights for the first half. For the past few years, growth for you was around 12% to 13% organically. Over the last 4 to 6 quarters, though, we have lifted that to 15% to 16%, with revenue up 16.2% for H1 FY '27, which is ahead of the guidance we stated. Importantly, we achieved this step up in growth while expanding EBITDA margins by 190 basis points, to a 26.2% EBITDA margin for the first half, and that comes without any price increase for <<inaudible>>. Looking ahead, we are optimistic about continuing a similar growth and margin trajectory through the remainder of the year. What adds to our confidence is that this is not a one-off. Over the last 2 years, we have been deliberately laying the foundation to sustain and accelerate this growth while continuing to expand margins.
A dental network with centers around our labs, a richer business mix led by Specialty and TruHealth, standardizing our laboratory platforms, significant technology upgrades across the business, and a disciplined approach in our inorganic strategy. It's also worth noting that we delivered this growth in a quarter when the monsoon was one of the weakest in over 2 decades, with rainfall roughly 13% below normal and highly uneven across regions. The seasonal rise in acute and infectious diseases such as dengue, malaria, typhoid and viral fevers was therefore sporadic and varies significantly across their properties. Despite this, we still grew around 16%, which reinforces an important part of our business model — that our growth is not only dependent on <<inaudible>> spikes and demand. It's also driven by the underlying strength of our portfolio across chronic disease management, preventive care and specialty testing, alongside the continued expansion of our network. Let me now share a perspective on the industry, the regulatory environment and our strategic priority. The broad picture of the industry remains consistent with what we have shared with you before. The market is stable and the structural shift from unorganized to organized segment continues, driven by a greater emphasis on quality and accuracy, rising demand for specialty testing, technology-led convenience, and the move to preventive health care and wider access in Tier 2 and Tier 3 markets.
Diagnostics isn't just a business where price is the driver — it's a fundamental business powered by science, accuracy, service quality, and the trust that doctors and patients place in it. To put it simply, the market is shifting toward quality and science, and that is precisely the environment Metropolis was built to compete in. What's new today, and what I'd like to focus on, is the government's increasingly constructive role when it comes to health care. Over the last several months, we've watched the government act to raise the bar for the diagnostics industry on quality, transparency, and access rather than trying to control price. Taken together, these developments are moving the industry in a direction that clearly favors organized, compliant players such as Metropolis over unorganized ones, which don't necessarily concentrate on quality and service. First, on the price cap for pharma products or hospitals: there's been considerable discussion about pricing control on drugs and consumables that hospitals sell. Let me be clear — this has no bearing on our business, whether financially or operationally. These measures target hospital pricing. They don't extend to diagnostics, and there's no move toward price capping or price parity in our segment. Pricing for diagnostics at organized chains is also transparent and, in most cases, significantly lower than comparable tests in a hospital setting.
Next, the requirement to show rates at centers — displaying rated centers at the point of service — is a change we welcome and fully back. Operationally, it makes very little difference for us. At Metropolis, patients already know the price before anything happens. We take a payment first, then deliver the rest. In a hospital, it works the opposite way: the service comes first for us, and the patient finds out the bill afterward. Making rate display mandatory moves the rest of the industry nearer to how we already run things. It narrows the information gap that opaque, unorganized players have depended on, and it lets patients compare like-for-like on both price and quality. Once the comparison is transparent, we believe our accreditation, our test menu and our service standards will speak for themselves. Third, the NMC advisory on digital authorization report. The National Medical Council Commission has recently clarified that a registered medical practitioner can remotely review and authenticate lab and pathology report using recognized digital signature subject to clear <<inaudible>>. This is a meaningful enabler for us in 3 ways. Number one, it improves quality. Strategy report is reviewed by a qualified pathologist exercising independent professional judgment.
Our lab information systems were already keeping full audit trails, authentication logs, and time staff and signing credentials on every report, and that lets us aim at a broader network base for specialty testing, while the talent pool sits in a single location. Now we can route a report to the right expert wherever they are located, instead of depending solely on whoever happens to be on site. A complicated hematology or oncology case from a small town can be reviewed by a specialist at our reference laboratory with the same rigor as it gets processed in <<inaudible>>. Second, it backs our rural and Tier 3 expansion. A practical constraint in <<inaudible>> has been the supply of qualified pathologists <<inaudible>>, and remote authorization lets us stand up many labs in these markets more quickly with a central pool of pathologists supporting them, while also improving turn around times and enabling round-the-clock reporting. All told, we view the shifting regulatory landscape as a clear tailwind. History shows that each time a formal regulation comes in, business shifts more from unorganized to organized. We expect Diagnostics to take the same path, and we are well positioned not only to adapt to these changes but to gain from them. Now let's turn to our key strategic priorities focus.
Science and technology continue to be front and center. Metropolis has always placed science at its core, and we keep investing ahead of the curve. Within Genomics, we're broadening what we can do in oncology, reproductive silt, and rare and inherited disorders. Genomics looks to us like a substantial long-term growth opportunity, and one where being signed with depth, interpretation expertise, and clinician trust are what decide things. We keep putting money into automation and AI throughout our labs, and we're rolling out AI along the value chain — from sample logistics and lab operations all the way to report validation, customer engagement, quality improvement, the debt, and productivity. Finally, protecting data and patient data is a duty we treat very seriously. We're well along in bringing our systems and processes in line with the digital personal data protection framework, which further reinforces the trust that patients and doctors place in us now. Let me take a moment on venture Healthcare, which we also view as among the more exciting growth areas for our business. During the past few years, Preventive Care has clearly become mainstream. Today's consumers are pharma health conscious and proactively pick regular checkups and early screenings instead of coming to a lab only when <<inaudible>>. That trend is showing up as strong performance for us, with our Preventive Healthcare revenue growing at about 20% per year.
So to keep that momentum going, we've been layering in allied services—things like basic radiology, doctor consultations, and bike checks—throughout our network at our own centers. That hands us a distinct edge when it comes to prescription completion, since patients can now finish their whole set of recommended end consultations with us in a single place, under one trusted brand. Moving forward, we'll be running pilots on some new <<inaudible>> preventive health care, consistent with our strategy of constructing a robust ecosystem of allied services around our Core Diagnostics business. We're eager to share progress updates with you once those pilots wrap up. Turning to our recent acquisitions and inorganic pipeline—every acquisition we've completed over the past year is performing well and integrating smoothly into the network. Topic in Daratun and Scientific in Agra are each growing in line with the company average, while delivering margins higher than the overall company margins, which validates both our selection and our integration approach. Core Diagnostics stands as a strong example of how we create value through strategic acquisitions, driving both revenue growth and margin improvement. On the revenue front, the acquisition has strengthened our capabilities, high-end specialized testing in oncology, an area where only a handful of players in the country have the required expertise while providing access to new clinician and patient segments.
What’s really driving strong momentum in the Specialty segment—which is still expanding at roughly 20%—is cross-selling our core specialized testing portfolio through a broader metropolis network, plus upselling high-end tests to the customers we already have. In parallel, by leveraging the core oncology and genomics portfolio across our network, we’ve sped up growth in our own genomic business. Turning to margins: core was at breakeven when we bought it 1.5 years ago, and now it’s producing margins in the near double-digit range. Given how much our genomics business has accelerated, we figure that over the past year our IRR on the core acquisition sits at about 30%, and that will only pick up further in H2 as revenue growth rises and margins widen. We’ve also finished a Plan B restructuring of the core team. Now that it’s in place, our attention turns to pushing revenue higher still. Together, <<inaudible>> Gavican Scientific have lifted the revenue contribution we get from Nobia to roughly 17% of our domestic revenue, and we expect that share to climb as these businesses scale. At present, Nordson is our fastest-growing region organically, thanks to better execution. Along with our on-ground presence and established brand equity, these acquisitions have let us reach deeper into these markets.
We view this as a stepping stone, especially when it comes to targeting micro markets where a persistent gap exists between demand and quality supply. Let me also share how we're thinking about the M&A market today, because it shapes the deal we choose to do more than the ones we choose not to do. Broadly, there are 2 kinds of businesses in the market: 4 quality businesses that are up for sale and struggling to find files, and some good quality businesses, which have been acquired at very high valuation. We have looked at these deals with past on them, as it's not possible to own a decent IRR. The math feels important when a Diagnostics Business is acquired at an 18 to 20 multiple of EBITDA; the return depends heavily on margin expansion. The diagnostics is not like the pharma industry, where the back end can be easily integrated and synergies flow through <<inaudible>>. In our experience, margins in an acquired diagnostics business fall during integration as quality systems, people and processes are brought up to standard and then may recover, but almost never then the level higher than when we started. Therefore, a dose entry multiple, the IRR on such deals works out to be less than 10%.
Conversely, if we buy companies at sensible valuations and then build the value ourselves across 3 years via our brand test menu, specialty portfolio, logistics and procurement, the IR we generate can come closer to 20%. That's the playbook we've used with <<inaudible>> scientific and core. Going forward, we'll keep actively assessing M&A opportunities, particularly in North India in pathology and ancillary services. However, we'll favor transactions delivering a higher IRR instead of paying very high valuations merely to purchase revenue. When we acquire established local brands at the right price, that gives us a head start in each micro market, and from there we can expand into surrounding peripheral markets by adding tests, building more organized logistics and sample movement, and deepening our connect with doctors and patients through digital channels and tech platforms. I'll now ask Suren to walk through the operational and financial performance for Q2 and H1. But before that, I just want to announce that the company has declared an interim dividend of INR 1 per share. Thanks, Suren. Over to you.
Thank you, Ameera, and good morning to all of you. For us, Quarter 4 was yet another robust quarter, with revenue growth of roughly 16%, which came in ahead of the guidance we had stated. What matters greatly is that we achieved healthy expansion in both the B2C and B2B channels, improved how we operate within the TruHealth and Specialty segments, and produced broad-based gains across every geography, reaching from metropolitan markets all the way to Tier 3 and Tier 4 towns. This shows how solid our diversified business model is and how well we can generate growth across channels, segments and markets. Patient volumes rose 10 percentage and test volume roughly 11 percentage, with <<inaudible>> arising from a richer test mix and improved realization. Crucially, none of this growth involved any increase in price. Across the first half as a word, revenue climbed 16.2 percentage, a distinct step-up from the 12% to 13% we delivered over recent years. At the same time, margin expanded 190 bps to 26.2%, which reflects the operating leverage in our business. Considering how consistent this performance has been and the momentum we are bringing into the second half, we anticipate these trends continuing for the remainder of the year. I also want to touch on a topic that has been widely discussed across the industry lately: the revision in CGHS rates has supported growth for a number of players in the sector.
The amount CGHS adds to our revenue is very small. Because of that, all of our growth has come from volume and mix. Now moving to how the channels performed and what other segments delivered. In quarter 2, our B2C revenue rose 17%, and it rose 17% in H1 of the year as well, <<inaudible>> with patient and test volume continuing to grow at a double-digit pace, up 13.5% and 11%, respectively. Digital engagement, tightly focused micro marketing campaigns, and a brand that keeps growing across geographies and segments all helped drive patient acquisition. The growth was broad-based across both mature and U.S. centers: existing centers posted same-store growth of 10% along with better retail productivity, while newer centers keep ramping up. In the quarter, we added under 116 collection centers, which brings our net additions to 700 over the last 24 months. The labs we set up in financial year '25 and '26 are also picking up momentum, and we are extending their reach further through a growing collection network so they can drive higher throughput. Our B2B business rose 15%, which reflects our focused approach to partner <<inaudible>> hospitals, clinicians, and quality-led institutions, where our scientific expertise and specialty portfolio give us a distinct advantage. Inside B2B, patient volume was up 7% and test volume was up 11%, meaning partners are sending more test patients our way — a clear signal that the value chain is growing.
During the quarter, we kept bringing on additional lab and hospital partners, and our B2B partner network has now passed 9,000 partners. Our partner portal has kept making it easier for partners to collaborate with improved visibility, coker turnaround, and seamless access to our entire test menu. On TruHealth and Specialty, both of our strategic growth engines keep delivering strong performance. Specialty grew around 20%, backed by broader adoption of advanced tests, deeper engagement with clinicians, and cross-selling of the core oncology portfolio. We added 4 specialty and super specialty tests in the first half of the year, which gives us more headroom for growth. Specialty also creates a halo effect for our routine business — a patient who comes to us for a specialty test naturally ends up completing all their tests in one place. TruHealth, our preventive health care franchise, also grew 20%, driven by integrated wellness offerings and focused digital acquisition. Packages that include radiology are gaining traction, supported by add-ons such as doctor consultations, vital checkups, and ECG. We're now adding these allied services not only in our own centers but also across the Metro franchise network, which helps us improve prescription completion and offer patients a complete health care experience under one trusted brand.
On the performance side, looking at regions, growth was spread widely across geographies rather than being confined to our core areas. Tier 3 and rural centers were out in front, posting revenue growth of roughly 20%. Combined, those centers now represent 26% of our domestic revenue, which shows our expansion past the metros is working. Each of the 4 geographical regions delivered solid growth once more this quarter, with north standing out in particular. North India, now bolstered by the acquisitions we made, accounts for about 17% of domestic revenue. Let me walk through our priorities for the second half of the year. Adding access centers, both to reach the peripheral areas surrounding our newer labs and to deepen coverage in markets where we already operate. That means quicker B2B partner onboarding, with tighter emphasis on the special reed partnership, mini hubs that move testing nearer to the patient in basic radiology and allied services, plus better turnaround times, and lifting retail and center productivity by extracting more from each center we already have. And naturally, we'll stay focused on Tier 2 and Tier 3 markets, where better access to health care is building a big and expanding pool of new patients. Now let me turn to margins and the trajectory of improvement. EBITDA margins came in at 27.2% for quarter 2, up 180 basis points year-on-year, which is comfortably above the guidance we gave of 125 to 170 basis points.
The gain was driven by volume-led operating leverage, strict cost discipline, and consistent advancement on our productivity agenda. What makes us confident is that margin expansion is now sustainable, as our operating metrics clearly show. Productivity per employee has risen, since our manpower base has stayed fairly steady across the last many quarters while cash volumes climbed roughly 10 percentage to 11% year-on-year. We're expanding the business without adding team members proportionally, which lifts productivity and operating leverage. Sample process per lab has gone up per day. That means every lab handles larger volumes on an unchanged fixed cost base. Gross margin improvement has been our top priority; our laboratory platform transition, which I mentioned earlier, standardizes our network on a shared test menu, equipment, reagents, and turnaround times while consolidating vendors, and it will be finished in quarter 3, which will help the growth -- gross margins; also research test mix will support an uptick in gross margins. Step by step, we're swapping out many manual processes for technology throughout operations, from sample logistics to reporting and back-office functions. Network density keeps rising as we add centers near existing labs, moving our center to lab ratio from 24:1 toward 30:1 and then 35:1 over the next 2 years.
Specialty economics and TruHealth are contributing a growing share of revenue, so our business mix keeps premiumizing. Now let me discuss our technology road map. The second half will also be an important stretch for our technology transformation. We'll be rolling out a new CRM platform, a dynamic pricing engine and a new sales app for our field teams, and we'll enhance LIMS integration capabilities across our laboratories. Through <<inaudible>>, we're also working toward seamless integration of hospital portals with our systems, empowering our hospital partners with streamlined workflows, better connectivity and greater ease of doing business with Metropolis. We're transforming our finance function as well, and we've launched a comprehensive program to reengineer our end-to-end finance processes across all work streams. Alongside these initiatives, we're scaling our AI applications across customer engagement, laboratory, operations and quality. Together, this technology investment will make us faster, more data-driven and more productive while strengthening the overall experience of our customers and partners. Lastly, on the pricing front, our last price increase was implemented in January 25. And we're currently evaluating the possibility of the next price revision, maybe early next year. This is being considered in light of the increase in our operating input cost, transportation and logistic cost, service costs, amongst many other expenses.
With the solid volume momentum we're seeing and the structural move toward trusted organized players, we think there's space for a measured price increase that lets us pass along part of these cost pressures without meaningfully affecting volumes. We'll take a data-driven approach, with how much we revise set for each micro market according to peer benchmarks on market share, competitive intensity, and brand equity. We expect to roll this out in quarter 4 for part of the business. With that, I'll hand the call to Sameer, who will walk us through the financial highlights. Thank you, and over to you, Sameer.
Thank you, Suren, and good morning to all of you. I'd like to take a few minutes to take you through the main financial highlights from quarter 2 of FY '27. In quarter 2 FY '27, revenue came in at INR 297 crores, up 16% year-on-year, helped along by growth of 10% in patient volumes and 11% in tax volumes. For the quarter, B2C revenue rose 17% year-on-year, while B2B revenue was up 15% on the same basis. Our focus segment kept up its momentum. Segment 2 delivered 17% of revenue and expanded 20% year-on-year, and specialty accounted for 50% of revenue and also grew 20% year-on-year. Turning to margins for quarter 2, EBITDA reached INR 135 crores, a rise of 24% year-on-year. EBITDA margin widened by 180 basis points, reaching 27.2%. That came to INR 75 crores, up 43% year-on-year. That margin widened 290 basis points to 15.2%. This bank margin is the highest we have seen in the post-COVID period. On the balance sheet side, net working capital days for our network were 13 days, versus 16 days in FY '26. This reflects efficiency gains. Cash and liquid investments totaled INR 348 crores as of 30th September 2026, compared with INR 203 crores as of 31st March 2026, which gives us a strong cash position to fund additional organic and inorganic growth.
With that, I'll open the floor for questions and answers.
<<operator_script>> Our initial question is from Surya Narayan Patra of PhillipCapital India Private Limited.
Yes. Congrats on those strong figures. My first question concerns the count of tests per percent that we're observing. So actually, TruHealth has performed exceptionally well, and the momentum we've been seeing there has been consistent. But even so, the tests-per-percent figure, if I look at it, sits at only around 2, which appears lower than the industry. Is that because a big share of the test volume we're seeing is sickness tests or specialty tests, something along those lines?
So here's what happens on our end: a TruHealth test or a wellness package, we can't treat that as a single test. We don't tally it as 8 or 10 tests, and each of those wellness packages contains various components — up to maybe 50 or 60 <<inaudible>> as well. But we simply count it as just 1 test. That's why — even though TruHealth is growing by 20%, all of those are being counted as 1 test. So that's the reason you're seeing the number the way it is.
Alright, my second point concerns the genomic and cancer volumes here. So, as you can see, we've been observing a fairly consistent, sequential improvement in the specialty revenue share, particularly following the acquisition of the Core Diagnostic. But since that's now fully integrated into the business model, we're focusing more on the genomic side and all of that. So what share would these 2 specialty areas have in the overall picture? And what mix can be attained, let's say, in the next couple of years' time?
Your question is about how much of the total specialty test comes from oncology, correct? Is that what you're asking?
Yeah, genomics and oncology.
Yeah. Look, oncology makes sense because, in fact, we were already performing oncology testing prior to the Core acquisition with the base oncology test — we used to do that, right? So oncology accounts for a big share of the total specialty test. Genomics is still early for us. Over maybe the last 1.5, 2 years, we've been doing genomics. We're still just building out the genomics portfolio. So I mean, genomics and oncology combined will make up a substantial share of the overall specialty portfolio.
And I think both of these portfolios are going to keep growing faster than the average company growth. So we believe the opportunity for genomics is quite large. And as Suren mentioned, we're in the early days. So over the next years to come, we continue to expect to see significant acceleration in that area.
Moving on, regarding the center-to-lab ratio, you've been observing a fairly steady enhancement, and we're aiming for an improved figure as well. So on that subject, could you just shed some light on how this NetLink program or the <<inaudible>> partner portal initiative is working. So those are, in a sense, assisting us in genuinely growing the franchise count.
Let me take just a couple of minutes to walk through this whole thing. First, we've stopped adding any more new labs. And we still have 750 towns for operations, right? Then we're adding collection centers in those 750 towns, so that's where you're signing—where your denominator stays constant while your numerator rises. And only in existing markets—we're not moving into additional markets. So that definitely gives us that center-to-lab ratio climbing each quarter, right? And we said we'd bring it up to maybe close to 30 by the end of this year, and then maybe by the end of next year to <<inaudible>> ratio. I think that program remains very solid. And the other piece is that we also—when we bring on partners, we also have to retain those partners, make sure they're happy, that they make money, and that they enjoy doing business with us. That's where the metaling comes into play. The metaling is simply an engagement program between the partners and us. I mean, in the portal, we can see all their test menu, the price, and they can see their statement of account.
They can view their daily figures, their target compared with actuals. If we provide any extra programs and incentives, et cetera, to them, they could see that too. And we also do engagement with the partner on an annual and quarterly basis. That is essentially the metaling program. So with the metallic program having been implemented for 18 months now, it's done. At present we're seeing very high retention among our partners. We have very low single-digit partner churn at this point versus what we used to do maybe close to a 2-digit number previously. So the same partner, growing volumes, and staying put with us in the same geography is really helping us achieve overall volume growth in these Tier 3, Tier 2 markets.
My reason for raising this was simply to ask, sir, whether we are taking any different steps aimed at speeding up growth in the franchise account, since that is what has been driving the momentum we see in Tier 3. That was really the question.
That's precisely the response I gave. First, you're adding more centers — and second, we're holding on to the franchises, since the majority of centers bring it in via franchises. Previously, we had greater attrition among channel partners; through the metaling program, the partner portal, making business easier to conduct, and so on, partner retention has improved. As a result, we're seeing a significantly better ratio.
Alright, just one last clarification I was hoping for. You see, with the Barista government telling hospitals that all procedure pricing needs to be, sort of, <<inaudible>> publicly — so is that likely to have some kind of positive effect on the volumes we can think about?
As I believe Ameera said in our remarks, making rent rates public is something we see as a positive change. In the way we operate, we quote the price to the patient before anything else, and he or she hands over payment first, then the test is carried out — that is how it works with us. And we would be more than glad to post these rates at every one of our centers, on our website, and so on, so that in any case the customer is able to see all the pricing; from where we sit, this is a very welcome change. It is a very good move.
<<operator_script>> Our following question is from Kunal Thanvi of Banyan Tree Advisors.
I had 3 questions. First, about the 60-minute test we launched in Mumbai — I wanted to get a sense of the traction there, and also whether those are cities we've added under the instant booking kind of model. My second question concerns the regulatory changes you mentioned in your opening remarks, Ameera. What I'm trying to understand is this: the organized sector has already been struggling somewhat over the last 18 months or so, and that shows up in all the National Labs numbers, because we see growth — there's been some step-up in the growth. Do you think this could make the intensity of the shift from unorganized to organized become reasonably harder, with regulations also supporting quality and standardization in terms of reports, et cetera? And my third question is about competition and market share in 2 specific markets — one is north, because with core we've entered that market, and perhaps this is the first time, and we're seeing that we're doing well in the north. So I wanted to understand how we're doing vis-a-vis the competition?
Then second, in our home market — Mumbai — from an overall perspective, we notice the other 2 players, namely, say, suburban and the other one, are both ramping up quite aggressively when it comes to brand communication and lab additions, et cetera. So do we anticipate any shift in market share within our core market, or are we managing to retain our share in Mumbai? Since 2 years back, I recall we were also gaining share in Mumbai. So those are the 3 questions.
I’ll respond to that question now, and afterward we’ll have discussion <<inaudible>>. So when you examine the industry, I mean, there’s customer.
Ladies and gentlemen, the management line has been disconnected. Please hold while we quickly get the weakening. Thank you. Ladies and gentlemen, the management line has been reconnected.
As I mentioned earlier, regarding the industry side, the shift from unorganized to organized has clearly been underway for some time now. And like we said, it won't resemble a hockey stick, though a handful of incidents have acted as catalysts. Take COVID, for instance — one clear trigger was that of 300,000 labs across the country, just 2,000 received approval to actually conduct COVID testing. So during those few years, those 2,000 grew more visible, more brand focused, and quality moved to the forefront. That's one catalyst that accelerated the shift toward the organized market. The second thing, clearly, again during COVID, was technology adoption. As people became very accustomed to e-commerce, home-based things, and technology serving as a convenience, they began seeking out health care providers capable of delivering that kind of technology — which explains why you've seen organized hospitals and organized diagnostics expand faster afterward, since clearly we're able to implement the technology requirements consumers have. So if government regulation arrives in a positive manner, it will only benefit the organized players.
So here's the thing: as organized players, we already satisfy every one of those minimum standards today — but that's certainly not true of everyone else in the industry, and the folks in the unorganized space aren't necessarily complying with them. That's what creates a split in the market. So if regulation arrives, it will definitely push more people into an apple-to-apple comparison, which does mean that many players who can't hit those requirements — we're talking very, very small subscale levels — will probably have to begin winding down. And we've watched that play out over the last few years, even without any government relation, as quality comes first, as consumers grow more conscious, as specialized testing increases — something the unorganized guys can't do — we've seen smaller players shut down and become unable to operate in the market. And even within the organized space, while we saw plenty of competitors jump into the industry over the last 7, 8 years, even with deep pockets, they haven't been able to scale profitably, and we see those shut down as well. So I think this is 1 industry where building a strong brand based on science <<inaudible>> or whichever model you follow, and having trust, really hands you a first mover advantage.
Suren has the chance to step in.
Yes. Okay. Let me address your first question about Instar, specifically the 60 minutes of homeless services. We launched that in Mumbai and saw very good traction. We were also pleasantly surprised to find that, much like e-commerce, people wanted home services delivered faster. Normally, we assumed health services were planned maybe in advance or something like that. But after launching these services, we're seeing good traction. So we're able to serve our customers in almost 100 — close to 100 percentage of the cases, we're able to meet the 60-minute services whenever they're requested. So we've found good traction and forced Mumbai. We've launched it in Chennai. We could find equal enthusiasm in Chennai as well. So now we'll take this forward. I think in the month of November, 1st week of November, we're launching it in Bangalore. So <<inaudible>> services is definitely now seeing some headlines now. Now coming to your third question, the first part was about the North business — why and how is it doing? So definitely, see, one is the core dynamestics. And secondly, we also had Agra and Daratun, which is helping us in terms of growing in the north.
And on the whole, in certain markets outside of core Agra and <<inaudible>>, we've shifted toward the B2B model, and in places like the rest of and Upper North, and then Delhi, et cetera, we're likewise seeing solid traction from B2B hospitals on the specialty business. So all of it together is helping us grow the North geography, and we'll keep putting in our best efforts and not to further grow. And also, there was another part of -- in the third questions regarding Mumbai market share growth, et cetera, Look, we keep performing very well in Mumbai, and our center expansion and all our productivity and other initiatives around the existing centers, et cetera, keep doing well. if you've seen our report, we already stated 16%, <<inaudible>>, the growth in the West market for us, largely pirated by markets such as Mumbai, Pune, <<inaudible>> et. cetera. So we keep doing well. I mean I won't be able to answer your question on the market share because no credible data is available on the market share. You can compare the growth of the operator that you're talking about and our growth, and then you can figure out who is gaining more traction actually.
Of course, that's fair. I get it. Just one final follow-up on <<inaudible>>: do you think this could deliver new growth for us, or is it really more a matter of channels being rerouted? And if that's the case, does this channel end up costing you more than the 1-day delivery type of model?
No. So this is definitely what we're seeing — most customers right now are existing ones coming to us asking for <<inaudible>> services, but we're also bringing in new customers, right? And as we keep running this program, we're confident we'll attract more and more new customers. As for the cost, that's not really the issue — it's simply a matter of needing to keep certain slots available, and it's more about planning and making sure our applications fit the customer's immediate requirement, et cetera. So it's not necessarily going to cost us more.
There's a real benefit that comes with being an omnichannel operator — one that runs brick-and-mortar locations alongside home services — because you can deploy your resources across several channels, unlike the pure home-visit players, who must keep hiring more people each time they add a route. So for that reason, as Suren pointed out, our cost doesn't end up higher, since we can leverage those resources via branches and via our brick-and-mortar centers too.
Sure. Does that also mean that because of this, your productivity per resource can go up?
You're right about that. Throughout this year, we have the potential to achieve improved productivity.
Our following question is from Tausif Shaikh at BNP Paribas.
Surendran, during your opening comments you mentioned that EBITDA margin expansion for FY '27 would fall within a range of 120 to 170 bps. Is it correct to say you are changing the guidance you gave before, which sat at the upper end at 150 bps?
As we mentioned, during the first half we saw roughly 180 to 190 bps of EBITDA growth, and we expect that pattern to carry on through the remainder of the year too.
All right. And regarding the price increase you mentioned would come in the fourth quarter — I just want to get a sense of it: would that apply across the board, or is it going to be limited to B2C, or perhaps to one particular region?
Well, at this point <<inaudible>>. I mean, it's not necessarily limited to any particular region. We're simply looking at every possibility, and we're running all our analytics right now. Price changes will differ across different micro markets. So exactly will go to each of the markets. It's too early for me to comment on it. But we are working on it. It will take a couple of months for us to do a complete groundwork before we go and execute it.
The next question is from Anshul Agrawal at Emkay.
Let's start with margins. My understanding is that we previously provided medium-term guidance of margins rising to 25%, 28%. Could we look at this as staggered expansion, only because from what I can tell, price increases, operating leverage, not setting up too many labs, et cetera, since metro doesn't require it, would kind of speed up our margin trajectory. So should we kind of think about margins getting to that range very quickly? Or should you think that over the medium term, we have the ability to go beyond this range as well?
Yes. So, Anshul, what we see driving the EBITDA margins higher is essentially a few things — first, of course, it will come from operating leverage. And second, I mentioned the lab platform transition, which is nearly wrapping up by the close of this quarter, so for the quarters ahead, I'll receive the complete benefit of the lab platform changes. And the productivity initiatives as well — many things have already been done and more are going to be done. So those are the things that are going to give me the benefit on margins. And of course, once we begin doing price emissions, that too should help us in improving the margins, right? But at the same time, we are also — like I said, we are expanding some 25 mini hubs and we are trying to bring many other products onto the retail side. So there are some investments as well that we will make in parallel, which will help us — which may cost us a little bit more. So net of it, we clearly see an opportunity to improve the margins, perhaps 125 to 150 bps in the coming years as well.
Understood. The second question concerned the comments we made during our opening remarks. My understanding is that this regulation deals with remotely approving or essentially signing off on these reports, and that is already established at least in radiology. Has anything changed significantly on the pathology side, as well as on the package front? Could you expand on that a bit?
Previously, the regulation in place came from the National Medical Commission, and on top of that, every state sets its own rules too. At times those rules conflict with one another. At other times they overlap, and there was a considerable degree of uncertainty regarding what the rules actually were. In certain states, they held off on deciding whether remote authorization was permitted. So although we have pathologists in each lab, physically present and examining slides through the microscope, the concept was to leverage your specialist based in Bombay to sign off on a reporting partner, since clearly the doctor you bring in as a pathologist won't be a specialist in every area. Full clarity on this was absent from the earlier regulation, and it got debated across multiple geographies. So now, this NMC clarification provides certainty about precisely what you may do and what you may not do, which is helpful for change like us, because as we said, you can deploy your best talent wherever they happen to be to approve reports even in a small market, delivering improved quality to patients, and as a result, that improved quality should translate into better business in those markets.
I hope that clears things up.
Does it? So are we talking about this at a pan-India level? Is that right?
That is correct.
Mohan has one final question on the books. Given that we won't be adding any further lapse, could you assist us with the CapEx guidance for the current year?
As we've said before, our CapEx is going to fall in that 4 to 5 percentage range overall, correct? And that's the way we kept it last year too, with a comparable range this year — I mean, roughly INR 65 crores to INR 70 crores is the usual CapEx for us, all things included. So I mean, we ought to be in that same range this year too.
Shrikant Akolkar from Nuvama has the next question.
I've got two questions regarding the price increases. So about what you said on price increases — do you think there will be price increases at the industry level? And what sort of response do you expect from the unorganized diagnostic companies?
Okay, so I can only speak for my own company here, right? I can’t say what’s going to happen across the rest of the industry’s organization, because our reason for doing this is that for 2 years we haven’t raised prices. There are lots of cost components that have risen — inflation, as all of you are aware. The biggest cost, transportation cost, service cost <<inaudible>>, all of it has climbed over the last couple of years. And I think — from our standpoint it’s only fair to look at a price increase now. I’m not — I don’t know if the rest of the industry will act the way we are, or what will happen with the unorganized sector; Ameera, we’ll be able to comment on that.
Got it. For a long time, the diagnostics-focused player held the view that prices should stay steady. They also kept expecting volume growth to arrive, and that is now occurring. So what is genuinely different? Since a few years ago there was a price hike, and now you are mentioning price hikes as well. Therefore, aside from cost pressures, are there any additional factors behind raising prices at this moment?
Look, one thing we need to keep in mind is that raising prices isn't anything new. Organized chains, as well as unorganized ones, have been doing it annually or every 2 years for <<inaudible>>, correct? This isn't some new development. So what we're simply saying is that the sole reason we didn't do it last year was a GST law that came into effect and provided some input benefit. And so, for 1 year, we hit pause, and I believe a few of our industry peers also made that call for that 1 year. Just to ensure all of us stay very compliant on the tax front. And so, apart from that, yearly price hikes have been a standard practice. Every 1 or 2 years has been the usual pattern. We don't accept the idea that the unorganized industry refrains from raising prices. In fact, you have to understand that at the local level, the unorganized pathologist doesn't get much volume growth. And really, increasing price is the sole route available to them for growing revenue. So typically, they do raise prices each year, and that has been the industry norm.
Got it. One final question about Core Diagnostic. My recollection is that in the prior quarter we had a high single-digit exit run rate on margins. Could you give us an update on that?
During the previous quarter, Core Diagnostics delivered a margin in the double digits.
Our next question is from Garo Pharma at JM Financial.
I want to begin by saying congratulations on a really strong set of numbers. Just for bookkeeping purposes, at a single <<inaudible>>, I would use it if you could give us some kind of FY '27 guidance on both top line growth and EBITDA margin?
For FY '27, right? So we did mention that the first half of the year had roughly 16 percentage as a good revenue growth, along with about 180 to 200 bps margin growth. So we expect a similar trend to continue for the rest of the year as well.
All right, that's clear. Thanks.
Shyam Srinivasan from Goldman Sachs has the next question.
Turning to a few of the points raised regarding growth by region. Ameera, I believe you said the North is the fastest-growing organically. Yet when I check Slide 9 of your presentation, the figure there is 12%. So there may be a way to square the two. If you could clear that up.
Yeah, that's right. I don't think it's a per-person figure — we said the contribution from North has risen to 17%.
Alright. I realize we just talked about growth, though perhaps I'm mistaken there. Fine. My second question goes back to a few of the opening comments regarding hospital pricing and the sort of margin caps those industries face. Looking at the Diagnostics TAM, roughly 35% of it sits with hospital labs, correct? So, supposing — just a hypothetical here — that price caps were applied to diagnostics as well, or at least a standardized rate, I believe you said earlier that your rates run significantly below those of hospital labs. Would that therefore represent an incremental opportunity from a B2B standpoint? How would you view that?
Look, the agreements we have with hospitals sit at a set price. And beyond that, the rates they already have with us are discounted. Whatever price they charge the customer will have to fall within what the cap allows, correct? So the pricing I have with the hospital really doesn't shift. It rests on a standard, what you'd call a contracted-price foundation.
Mine is really more of a chance than a question. Do you figure their piece will get smaller? I mean, why would 35% remain with them when they aren't competitive on cost, when prices for them are probably under pressure now, and they have to outsource more to companies like yours? That's the logic I'm looking at.
Okay, so we don’t have visibility into that, because I’m basing this on what I see happening inside hospitals. Most of them — you see, they run their own labs. A lot of hospitals operate their own labs. The only testing they send out to us is what they don’t perform in-house, and that has lifted volume for most of them, hospital by hospital — only the specialty testing gets outsourced to us. And that was under a price contract with them, and that isn’t going to change. But as for whether there’s an opportunity for them to stop doing some of the testing and hand it — I mean, also hand it to us — that’s unlikely, because they already have the lab and the arrangements in place, so why would they also send out those tests when they already have the lab for them.
The reason being that the rates the government appears to be proposing make prices unsustainable at this point, and on top of that, their cost structures are burdened.
We’ll need to see whether the <<inaudible>> change truly affects hospital margins, since every hospital’s exposure to oncology drugs differs. On the hospital results that came out only in the last few days, we haven’t really observed any margin impact so far. So I think we first need to wait and see whether hospitals’ margins are affected by this. The reasoning is, you’re right, that let’s try to reduce costs elsewhere. Whether that leads to more test outsourcing, I think we’ll need to wait and see. I don’t think there’s a clear direct link at this point. I mentioned that the North zone is growing fastest. We said that for H1; the data you’re looking at is for Q2.
All right. And for H1, what figure would that be — Ameera, my apologies, that isn't in the presentation.
Roughly 16%.
Our next question is from Akash Shah at Investec.
Yes. Congrats on the strong results. Most of the questions have already been covered. I just wanted to ask about the patient growth we've been seeing over the last few quarters. Patient growth has suddenly climbed from roughly 5% in the fourth quarter of FY '25 to now high single digits to mid-double digits. So is there something structural behind the high new patient numbers, the patient growth you're seeing?
Look, from our perspective, patient volume growth was roughly 7 percentage about a year ago. It has since risen to 10% — let me just get the numbers part out first. And there are 2 or 3 things happening that are helping us achieve that patient volume growth. First, all the new centers and labs we set up over the past, say, couple of years in Tier 2 and Tier 3 towns are now becoming productive. We're also witnessing strong traction, with people wanting quality diagnostics done in these fine labs — the branded lab. So we're clearly seeing solid walk-ins at these centers. That's one reason. And second, our engagement with existing customers via customer life cycle management, the digital platform, and so on also sped up, and we're seeing a greater number of customers — the same customer returning to our network for subsequent services as well. So those are the 2 major things I can point to that are helping us push patient volume growth into double digits.
Our following question is from <<inaudible>> at <<inaudible>>.
Regarding the Tier 2 market margin, it’s at a pro level, and there’s no major acquisition plan for this year. Could you help us get a sense of the growth opportunities in that market and which specialties are driving demand there? Also, what’s the outlook for price increases and the pricing structure? That’s all from my side.
Turning to Tier 3 markets, growth there is running at roughly 20 percentage, and Tier 3 already accounts for 26% of our contribution at this point of time, with that share gradually rising. And now, as I mentioned in my earlier comments, we are adding more and more centers across Tier 2, Tier 3, and Tier 4 towns. And we will accelerate further the rate at which we add centers. And you will see more pace picking up in center addition in Tier 2 and Tier 3 markets in the days to come. So that's another way for us to make the best out of the Tier 3 opportunities coming in. And to your question of whether it is specialty or whether the routine test, which is coming from here, it's actually both in the Tier 3 towns, when you set up the lab and there's a collection center, normal routine and semi special test also comes there. But also there's an opportunity for us to pick up sample from there, which is on the specialty and send it to the nearest reference lab and get it tested. So we are seeing both routine as well as specialty tests coming in from Tier 3.
On the pricing piece, I believe I’ve already said that we’re looking at a price increase early next year. The basic groundwork is underway right now, and it takes a bit over time, and normally we do it for B2C. Then different markets, micro markets may have different price revisions. So it’s early days, but perhaps in the next month, 4 to 6 weeks’ time, we’ll be able to do the world working, and then we’ll be able to get this going maybe early next year.
Thanks. That brings us to the last question for today, ladies and gentlemen. Our question-and-answer session has now ended. I'll turn the conference back to management for closing remarks.
Thanks, everyone, for being with us today on this Q2 earnings call. As you can likely tell from our chat this morning, we're feeling quite confident and positive about where we're headed. We believe not only that our execution levers have grown stronger, and because of that the growth rate has shifted to a different benchmark than before, consistently over the last 4 to 6 quarters. We've managed to do this alongside very strong margin expansion, and we expect that to keep playing out not just in H2 of this year but over the next few years too. As Metropolis keeps building strength and depth on the pathology side of the business, as we said, we're piloting a few ancillary services and preventive health care and otherwise. And as we move through these pilots, we'll be glad to come back with information and imports around whether we plan to scale them. But we will be making some of these investments, which are asset light, over the next couple of quarters. So that potentially creates a second growth engine for Metropolis besides pathology too. So thank you, and we look forward to chatting with all of you at the end of Q3 in early Q4.
Thanks a lot. And happy Diwali to everyone.
Thanks. That brings this conference to a close on behalf of Metropolis Healthcare Limited. We appreciate your participation. You can go ahead and disconnect your lines now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Metropolis Healthcare Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Metropolis Healthcare Limited earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.